Of note, using PDX model transplanted with human FLT3-ITD+ AML cells, Maifrede et al. showed that AC220 (10 mg/kg/day, 7 days) prolonged survival of primary treated mice, but did not change survival of 2nd recipient mice [50]. This evidence concerns the gene FLT3 and acute myeloid leukemia.